Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2009
-
By Donald Zuhn — Last month, the Manufacturing Alliance on Patent Policy (MAPP) released a report that indicates that the apportionment of damages provisions found in prior Senate (S. 1145) and House (H.R. 1908) patent reform bills would have adverse effects on the U.S. economy. In particular, the report concludes that an apportionment system…
-
By Christopher P. Singer — The U.S. Patent and Trademark Office sent out a series of e-Commerce Alerts on February 10, 2009, announcing that the existing pilot e-Office Action program will be made permanent and available as an option to all applicants beginning this March. The USPTO has been maintaining the current pilot e-Office…
-
By Donald Zuhn — Recently, we were contacted by Matthew Smith (at right), an associate in Foley & Lardner's Washington, DC office and an adjunct professor at the George Washington University Law School, who wanted to let us know about a treatise on inter partes reexamination that he had just completed. Prof. Smith also…
-
By Suresh Pillai —GeoPharma and Dr. Reddy's Resolve Patent Litigation Related to Claritin® Patents On January 20, 2009, GeoPharma, based in Largo, FL, announced the settlement of its Clarinex® (Desloratadine) ANDA patent litigation with Schering-Plough (based in Kenilworth, NJ) and Sepracor (based in Marlborough, MA) (see "Court Report," February 24, 2008). On February 20,…
-
By Donald Zuhn — Last month, in a notice published in the Federal Register, the U.S. Patent and Trademark Office announced that it would be holding a roundtable discussion regarding deferred examination on February 12th (see "USPTO Schedules Roundtable Discussion on Deferred Examination"). Today, the Patent Office provided additional details regarding the roundtable on…
-
By Donald Zuhn — Shortly before leaving the U.S. Patent and Trademark Office, former Director Jon Dudas was served with three last complaints from patentees seeking additional Patent Term Adjustment (PTA) for their patents. The three complaints bring the number of 35 U.S.C. § 154(b)(4)(A) actions to 14, involving 15 patentees and 21 separate…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Boehringer Ingelheim Vetmedica Inc. v. Merial Ltd. et al.3:09-cv-00212; filed February 4, 2009 in the District Court of Connecticut Declaratory judgment of…
-
February 12, 2009 – Patent Portfolio Strategies in the Post-KSR Environment (FX Conferences) – 11:30 AM to 12:30 PM (EST) February 12, 2009 – Stanford IP Litigation Clearinghouse: A Pioneering Database with "Life and Death" Statistics for Patent Litigators (Practising Law Institute) – 1:00-2:00 PM (EST) February 13, 2009 – Fourth Annual Workshop on Patent…
-
The biotechnology, chemical, and pharmaceuticals (BCP) technology groups at the U.S. Patent and Trademark Office will hold their next quarterly customer partnership meeting on March 3, 2009 at the USPTO's Madison Auditorium, 600 Dulany Street, Alexandria, VA. The schedule of topics for discussion include (all times Eastern):Morning Session • Greetings and Overview (10:00 – 10:15…
-
The Biotechnology Industry Organization (BIO) will be holding its Intellectual Property Counsels' Committee (IPCC) Spring Conference & Meeting on March 25-27, 2009 in Phoenix, AZ. The semi-annual IPCC conference will be open to the public for the first time ever. The registration fee for the conference ranges from $400 for BIO members to $700 for…
Patent Docs 